# A Study of ISIS 416858 Administered Subcutaneously to Participants With End-Stage Renal Disease (ESRD) on Hemodialysis

Study · id `cardio:ct-nct03358030` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03358030](<https://clinicaltrials.gov/study/NCT03358030>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03358030

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 213 participants.

## Technical summary

Registry record NCT03358030. Randomized; quadruple masking; primary purpose prevention. Start 2017-12-26 (actual); primary completion 2019-07-10 (actual). Results posted on 2023-01-20.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose prevention
- Phase: Phase 2
- Enrolled: 213 participants (enrolled count; ClinicalTrials.gov record NCT03358030, source copy `cardio:ctgov-nct03358030-2023-01-20`, retrieved 2026-10-26)
- Started: 2017-12-26 (actual) (ClinicalTrials.gov record NCT03358030, source copy `cardio:ctgov-nct03358030-2023-01-20`, retrieved 2026-10-26)
- Primary completion: 2019-07-10 (actual) (ClinicalTrials.gov record NCT03358030, source copy `cardio:ctgov-nct03358030-2023-01-20`, retrieved 2026-10-26)
- Completion: 2019-07-10 (actual) (ClinicalTrials.gov record NCT03358030, source copy `cardio:ctgov-nct03358030-2023-01-20`, retrieved 2026-10-26)
- Results first posted: 2023-01-20 (ClinicalTrials.gov record NCT03358030, source copy `cardio:ctgov-nct03358030-2023-01-20`, retrieved 2026-10-26)
- Countries: Spain (ClinicalTrials.gov record NCT03358030, source copy `cardio:ctgov-nct03358030-2023-01-20`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03358030-2023-01-20`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study of ISIS 416858 Administered Subcutaneously to Participants With End-Stage Renal Disease (ESRD) on Hemodialysis
- Acronym: EMERALD
- Condition: End-stage Renal Disease (ESRD)
- Intervention (Drug): ISIS 416858
- Intervention (Drug): Placebo
- Lead sponsor: Ionis Pharmaceuticals, Inc.
- Lead sponsor class: INDUSTRY
- Collaborator: Bayer
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry lists this organization as the lead sponsor: Ionis Pharmaceuticals, Inc. (`cardio:org-ionis-pharmaceuticals-inc`)
- Registry lists this organization as a collaborator: Bayer (`cardio:bayer`)

## Provenance

Content hash: 362d0511b1c57affb4b7016d1438086d3b230266ec09a404d9e5ffb685c4294b
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
